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Abstract  48 
Background: EUCAST has revised the definition of the susceptibility category “I” from “Intermediate” to 49 
“Susceptible, Increased exposure”. This implies that “I” can be used where the drug-concentration at the 50 
site of infection is high, either because of dose escalation or through other means to ensure efficacy. 51 
Consequently, “I” is no longer used as a buffer-zone to prevent technical factors from causing 52 
misclassifications and discrepancies in interpretations. Instead, an “Area of Technical Uncertainty” (ATU) 53 
has been introduced for MICs that cannot be categorised without additional information as a warning to 54 
the laboratory that decision on how to act has to be made. To implement these changes, the EUCAST-AFST 55 
(Subcommittee on Antifungal Susceptibility Testing) reviewed all, and revised some, clinical antifungal 56 
breakpoints.  57 
Objectives: To present an overview of the current antifungal breakpoints and supporting evidence behind 58 
the changes. 59 
Sources: This document is based on the 10 recently updated EUCAST rationale documents, clinical 60 
breakpoint and breakpoint-ECOFF documents. 61 
Content: The following breakpoints (in mg/L) have been revised or established for Candida species: 62 
micafungin against C. albicans (ATU=0.03); amphotericin B (S≤/>R=1/1), fluconazole (S≤/>R=2/4), 63 
itraconazole (S≤/>R=0.06/0.06), posaconazole (S≤/>R=0.06/0.06) and voriconazole (S≤/>R=0.06/0.25) 64 
against C. dubliniensis; fluconazole against C. glabrata (I≤/>R=16/32); and anidulafungin (S≤/>R=4/4) and 65 
micafungin (S≤/>R=2/2) against C. parapsilosis. For Aspergillus, new or revised breakpoints include: 66 
itraconazole (ATU=2) and isavuconazole against A. flavus (S≤/>R=1/2, ATU=2); amphotericin B (S≤/>R=1/1), 67 
isavuconazole (S≤/>R=1/2, ATU=2), itraconazole (S≤/>R=1/1, ATU=2), posaconazole (ATU=0.25) and 68 
voriconazole (S≤/>R=1/1, ATU=2) against A. fumigatus; itraconazole (S≤/>R=1/1, ATU=2) and voriconazole 69 
(S≤/>R=1/1, ATU=2) against A. nidulans; amphotericin B against A. niger (S≤/>R=1/1); and itraconazole 70 
(S≤/>R=1/1, ATU=2) and posaconazole (ATU=0.25) against A. terreus.   71 
Implications: EUCAST-AFST has released 10 new documents summarising existing and new breakpoints and 72 
MIC-ranges for control strains. A failure to adopt the breakpoint changes may lead to misclassifications and 73 
sub-optimal or inappropriate therapy of patients with fungal infections.  74 
Introduction 75 
The EUCAST recently revised the definition of the “I” category from “Intermediate” to “Susceptible, 76 
Increased exposure”. Before this change, the I-category was used in two very different scenarios. First, 77 
when a level of antimicrobial activity was associated with uncertain therapeutic effect. This implies that an 78 
infection due to the isolate may be appropriately treated in body sites where the drugs are physiologically 79 
concentrated (as is the case for some antibiotics in the urine) or when a high dosage of drug can be used 80 
(as is the case for fluconazole and C. glabrata). Second, intermediate was used as a buffer zone to prevent 81 
small, uncontrolled, technical factors from causing misclassifications and major discrepancies in 82 
interpretations, for example when the MICs for susceptible and resistant organisms overlap. 83 
 Obviously, the clinical implication of these two scenarios is very different. In the first, the organism 84 
is susceptible given the circumstances mentioned are met, whereas in the second scenario the MIC alone 85 
cannot inform whether the organism is susceptible or not. To separate these scenarios, EUCAST revised the 86 
definition of the I-category to “Susceptible, Increased exposure” when there is a high likelihood of 87 
therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its 88 
concentration at the site of infection. For the second scenario, an Area of Technical Uncertainty (ATU) was 89 
introduced as a warning to alert the laboratory to the uncertainty of the MIC result and that the laboratory 90 
needs to decide how to react to the warning before reporting a susceptibility classification to the clinician.  91 
Consequently, MICs falling in the former Intermediate category had to be reviewed and categorised 92 
as one of the following 93 
1. S (susceptible) when current evidence supports that there is a high likelihood of 94 
therapeutic success using a standard dosing regimen of the agent. 95 
2. I (Susceptible, Increased exposure) when current evidence supports that there is a high 96 
likelihood of therapeutic success because exposure to the agent is increased by adjusting 97 
the dosing regimen or by its concentration at the site of infection. 98 
3. R (Resistant) when current evidence supports that there is a high likelihood of therapeutic 99 
failure even when there is increased exposure. 100 
4. ATU (Area of Technical Uncertainty) to warn the laboratory staff that the value is in an area 101 
where there are interpretative difficulties. The reason is that a breakpoint is in a place 102 
where reproducible interpretation cannot be achieved. The ATU is not related to 103 
uncertainties in the testing procedures although the natural unavoidable variation in 104 
testing will influence the actions that may need to be taken. The ATU assumes that the 105 
susceptibility test is correctly performed and that the MIC value obtained is correct in itself. 106 
For the antifungal agents, the revised “I” category is therefore only applicable in situations where increased 107 
antifungal drug exposure can be achieved either because a dose escalation option is approved (example: 108 
fluconazole), because specific drug formulations of the same compound are associated with higher 109 
exposure (example: posaconazole gastric tablet and i.v. formulations compared to the oral solution), 110 
because high exposure can be documented through therapeutic drug monitoring (TDM, example: mould-111 
active azoles) or because the compound is physiologically concentrated at the site of infection (no good 112 
examples for antifungals (yet) but well known for some antibacterials and urinary tract infections). The 113 
latter is relevant for some antibacterials, for example those concentrated in the urine during urinary tract 114 
infections. It is, however, not a common scenario for the antifungal agents used for invasive infections, 115 
although it might be appropriate for some antifungals also used as topical agents when more data on MIC 116 
and outcome relationships for superficial infections emerge. 117 
The EUCAST antifungal susceptibility testing committee (EUCAST-AFST) has reviewed all current antifungal 118 
BPs and recently released a revised breakpoint table v 10.0 BPs and eight revised rationale documents. The 119 
process has involved a consultation among the national representatives in the full AFST Sub-committee 120 
(with representation of twenty nations) and subsequently a public consultation at the EUCAST website. 121 
Finally, the EUCAST steering committee has reviewed and approved the revised breakpoints. The important 122 
changes affect the majority of the former BPs set for Aspergillus and Candida species and are summarised 123 
in Tables 1 and 2 together with the key recommendations for MIC results in the ATU area. Below follows a 124 
description of the revised and new breakpoints and the considerations and evidence upon which the 125 
decisions were made. 126 
 127 
Amphotericin B 128 
Updates: The breakpoints have been revised for amphotericin B against A. fumigatus and A. niger. 129 
Breakpoints have been established for C. dubliniensis. 130 
Background: Amphotericin B is licensed for treatment of systemic or severe Candida and Aspergillus 131 
infections (and other fungal infections). Elevated MICs have been reported for some Aspergillus species 132 
including Aspergillus flavus, Aspergillus terreus, Aspergillus nidulans, Aspergillus lentulus and Aspergillus 133 
fumigatiaffinis [1]. In contrast, the in vitro activity of amphotericin B against species of Candida is mostly 134 
uniform. Amphotericin B has limited clinical activity against Candida lusitaniae although the MICs are 135 
comparable to those for the other Candida spp. This is due to a higher mutational rate and less fungicidal 136 
activity when exposed to amphotericin B [2]. 137 
Considerations related to breakpoints: The PK/PD relationship of different amphotericin B formulations is 138 
not well understood and the link between serum concentration profiles of different formulations with their 139 
efficacy is not well defined. Hence, the revised definition of the “I” does not apply for amphotericin B as no 140 
evidence exists that dose escalation is a valid option for isolates in the former Intermediate category. 141 
Consequently, the former Intermediate categories (for A. fumigatus and A. niger) have been reclassified as 142 
R. For Candida, the breakpoints have remained unchanged and for C. dubliniensis breakpoints have been 143 
established S ≤1/ R>1 mg/L (Tables 1 and 2). Epidemiological cut off values (ECOFFs) and tentative ECOFFs 144 
have been established for a range of organisms lacking amphotericin B breakpoints allowing classification 145 
of such isolates as wildtype or non-wildtype. 146 
 147 
Echinocandins  148 
Updates: The breakpoints have been revised for anidulafungin and micafungin against C. parapsilosis, and 149 
for micafungin against C. albicans. 150 
Background: The in vitro activity of the echinocandins against Candida species is not uniform. The species 151 
more frequently associated with human infections include C. albicans, C. dubliniensis, C. glabrata, C. 152 
parapsilosis, C. tropicalis and C. krusei, of which all but C. parapsilosis (and its sibling species C. metapsilosis 153 
and C. orthopsilosis) exhibit low MIC values. The underlying reason for the higher MICs for C. parapsilosis 154 
(and C. guilliermondii) is the presence of a naturally occurring amino-acid substitution(s) in the hot spot 155 
region of the Fks1 target enzyme, known to confer resistance in other species. Therefore, species 156 
identification is important and every attempt should be made to identify Candida to species level. 157 
Susceptibility testing of caspofungin has been associated with a level of variation prohibitive for breakpoint 158 
setting [3,4]. As there is a high degree of cross-resistance between the three echinocandins, isolates 159 
categorised as anidulafungin and micafungin susceptible can be regarded as susceptible to caspofungin 160 
until drug specific breakpoints are available for caspofungin [5]. Isolates with discrepant classification to 161 
anidulafungin and micafungin (e.g. Anidulafungin S and Micafungin R), should be further analysed with 162 
target gene sequencing as such isolates may harbour “weak mutations” causing a discrete loss of 163 
susceptibility. 164 
Considerations related to breakpoints:  165 
i) Echinocandins and C. parapsilosis. The C. parapsilosis wildtype populations were classified as 166 
intermediate for anidulafungin and micafungin with the former breakpoints [6]. The reasons were, a) that 167 
the outcome was numerically better in the fluconazole arm than the anidulafungin arm in the randomized, 168 
double-blind, non-inferiority trial of Reboli et al [7]; b) that echinocandin use has been associated with 169 
persistent candidaemia compared with both fluconazole and amphotericin B in subgroup analyses of 170 
randomized trials restricted to patients with C. parapsilosis [8]; and c) that an increase in C. parapsilosis was 171 
associated with caspofungin use at some centres [9,10]. An “increased exposure” option is not applicable 172 
for the echinocandins as no dose escalation option exists. C. parapsilosis was reclassified as susceptible for 173 
the following reasons: a) the echinocandins have been used for almost two decades as initial therapy 174 
(before the species identification is known) but also as continued therapy after the species ID is available 175 
because it is classified as susceptible by the CLSI [11]; b) in a recent retrospective observational cohort 176 
study, including 307 unique patients with C. parapsilosis candidaemia of whom 126 (41%) received 177 
fluconazole and 181 (59%) received an echinocandin, mortality was equal (fluconazole 9.5% vs 178 
echinocandin 9.9%, (OR 1.05, 95% CI 0.49–2.26)) [12]; c) fluconazole resistance is emerging in C. 179 
parapsilosis in some countries in which case echinocandins are a valid alternative considering the study 180 
above and the amphotericin B related toxicity [13–17]; and d) that treatment guidelines still emphasize that 181 
fluconazole is the preferred agent for C. parapsilosis when the isolate is susceptible thus limiting the risk of 182 
increased persistent candidaemia (Table 1) [18–21]. 183 
ii) Micafungin and C. albicans. The former susceptibility breakpoint for micafungin against C. albicans was 184 
stringent and only one dilution higher than the modal MIC (S: ≤0.016 mg/L, modal MIC 0.008 mg/L). 185 
EUCAST-AFST has been notified of frequent discrepant classifications of isolates as anidulafungin S and 186 
micafungin R in absence of Fks1 hot spot alterations [22,23]. EUCAST-AFST therefore collected Fks1 hot 187 
spot data for isolates with discrepant classification (micafungin of MIC 0.03 mg/L (R with former 188 
breakpoints) and anidulafungin MIC ≤ 0.03 mg/L (S with former and revised breakpoints)) and found no 189 
Fks1 alterations among 10 isolates (EUCAST-AFST, unpublished data). Additionally, reports of differential 190 
susceptibility to echinocandins confirmed in animal models are very limited and includes a C. glabrata 191 
where a the Fks1-S663F alteration conferred significant loss of efficacy to caspofungin (MIC 1 mg/L) and 192 
anidulafungin (MIC 0.5 mg/L) but not to the same extend to micafungin (MIC 0.06 mg/L) [24], and a case of 193 
C. albicans harbouring Fks1- R647R/G and P649P/L alterations conferring high level in vitro resistance to 194 
caspofungin and micafungin (MIC >1 mg/L) but not to anidulafungin (MIC = 0.03 mg/L) [25]. None of these 195 
cases involved isolates with the MIC combination of micafungin of MIC 0.03 mg/L and anidulafungin MIC ≤ 196 
0.03 mg/L. Therefore, an ATU has been introduced for micafungin MIC of 0.03 mg/L against C. albicans with 197 
the advice that the MIC should be interpreted based upon the susceptibility to anidulafungin (Table 1). 198 
 199 
Azoles 200 
Updates: Breakpoints have been revised for fluconazole against C. glabrata and established for fluconazole, 201 
itraconazole, posaconazole and voriconazole against C. dubliniensis. Breakpoints have also been revised for 202 
isavuconazole, itraconazole, posaconazole and voriconazole against several Aspergillus species and 203 
established for isavuconazole against A. flavus and voriconazole against A. nidulans. 204 
Background: The systemic azoles include fluconazole (spectrum includes Candida but not Aspergillus) and 205 
itraconazole, posaconazole, isavuconazole and voriconazole (spectrum includes both). The activity in vitro 206 
of fluconazole against species of Candida is not uniform. C. albicans, C. dubliniensis, C. parapsilosis and C. 207 
tropicalis tend to have relatively low MICs, whereas the MICs for C. glabrata tend to be higher. In addition, 208 
C. krusei is inherently resistant to fluconazole. The in vitro activity of the mould active azoles against the 209 
most prevalent species of Aspergillus is fairly uniform, although differences do occur even between the 210 
recently described and rarer “sibling” species belonging to the species complexes (e.g. Aspergillus lentulus 211 
belongs to the A. fumigatus complex and is multidrug resistant) [26]. Acquired resistance is reported with 212 
increasing frequency even among isolates obtained from azole-naive patients. The most commonly 213 
detected underlying mechanism is target gene alterations (cyp51A) with or without duplications in the 214 
promotor region of the target gene [27]. The degree of MIC elevation for isolates with Cyp51A alterations 215 
depend on the codon affected and the amino acid substitution, but in general confer a parallel MIC 216 
increase for itraconazole and posaconazole, and for voriconazole and isavuconazole, respectively [28–30]. 217 
Thus, correct species identification and susceptibility testing is of utmost importance. 218 
Considerations related to breakpoints 219 
i) Azoles and Candida: With the former breakpoints the entire wildtype population of C. glabrata was 220 
classified as intermediate for fluconazole [6]. This was in order to accommodate use in some clinical 221 
situations such as the treatment of urinary tract infections and mucosal infections managed in the primary 222 
health care setting, where alternatives are few. In cases where fluconazole is the only available antifungal 223 
agent for treating C. glabrata infections the use of a higher dosage may be required. However, with the 224 
revised definition of the “I” the concern was raised that an “I” category of ≤32 mg/L was too high with the 225 
new definition of the “I”. The original ECOFF of 32 mg/L was set including EUCAST, Etest and CLSI MICs. 226 
Therefore EUCAST-AFST collected new datasets and included only those performed with the EUCAST E.Def 227 
7.3 methodology [31]. Based on this dataset the ECOFF was revised to 16 mg/L. Consequently, the “I” 228 
category was maintained for C. glabrata but with a revised I breakpoint of ≤16 mg/L to acknowledge the 229 
use of fluconazole in some clinical situations provided a high dose (800 mg or 12 mg/kg) is prescribed 230 
(Table 3). 231 
C. dubliniensis is closely related to C. albicans. The susceptibility pattern for the azoles is almost identical 232 
for wildtype isolates of the two species with C. albicans being <1 two-fold dilution more susceptible to 233 
azoles than C. dubliniensis. Hence, in the absence of species-specific MIC-outcome data and a sufficient 234 
number of MIC distributions to set final ECOFFs and breakpoints for C. dubliniensis, EUCAST-AFST adopted 235 
the breakpoints for C. albicans for C. dubliniensis. 236 
ii) Azoles and Aspergillus: The former breakpoints included an intermediate category for itraconazole (2 237 
mg/L), posaconazole (0.25 mg/L) and voriconazole (2 mg/L) against Aspergillus species. The Intermediate 238 
category served in part as a buffer zone between S and R. But it also reflected that the outcome for 239 
infections involving isolates with intermediate susceptibility depend on a number of other factors. These 240 
factors include: 1) the heterogeneity of Aspergillus infections (ranging from slow chronic infections to acute 241 
invasive infections); 2) the heterogeneity of the host’s immune response (non-immunocompromised to 242 
severely neutropenic); 3) the variability in drug exposure (due to individual dosing, absorption and 243 
metabolism); and 4) the presence or absence of low grade resistance mechanisms (particularly in the 244 
setting of A. fumigatus) [31,32]. With the new definition, I requires a high likelihood of success with 245 
increased exposure. Increased exposure is in theory possible via TDM but concerns were raised because 1) 246 
evidence is lacking (apart from PK/PD data suggesting a relationship between exposure and outcome), 2) it 247 
takes time to increase exposure and TDM is not always available in a timely fashion and 3) invasive 248 
aspergillosis is a very severe infection with significant morbidity and mortality [33–35]. On the other hand, 249 
particularly for chronic and non-invasive infections, an MIC in the former intermediate range might be 250 
manageable and, with no other oral options, sometimes is the preferred option provided high levels can be 251 
obtained [36]. The revised breakpoints have been established to accommodate both aspects. Thus, an I-252 
category has been omitted and the R breakpoint lowered 1 two-fold dilution to prevent risk of 253 
inappropriate therapy of invasive infections involving isolates with MICs 1 dilution above the original S 254 
breakpoint. However, in order not to deprive patients with milder infection and few other alternatives a 255 
treatment attempt an ATU has been introduced for the previous intermediate category. For itraconazole 256 
and voriconazole, MICs in the ATU should be reported as R with the following comment: "In some clinical 257 
situations (non-invasive infection forms) itraconazole/voriconazole can be used provided sufficient 258 
exposure is ensured" (Table 3). For isavuconazole and posaconazole the former S breakpoints cut into the 259 
wildtype distributions (isavuconazole S BP = 1 mg/L but ECOFF = 2 mg/L, and similarly posaconazole S BP is 260 
0.125 mg/L but the ECOFF is 0.25 mg/L) because MIC distributions for wildtype and non-wildtype isolates 261 
overlap. The stringent breakpoints lead to many misclassifications of wildtype isolates as non-susceptible as 262 
noted in the rationale documents for these compounds [31,37]. Posaconazole resistance in the absence of 263 
itraconazole resistance and isavuconazole resistance in the absence of voriconazole resistance are rare and 264 
not to our knowledge reported with robust supporting clinical evidence. Thus, isavuconazole MICs of 2 265 
mg/L and posaconazole MICs of 0.25 mg/L are categorised as ATU with the recommendation to test 266 
voriconazole and itraconazole, respectively, and report as S or R depending of voriconazole and 267 
itraconazole susceptibility, respectively (Table 2). 268 
 269 
ECOFFs and clinical breakpoints 270 
Several factors are considered by EUCAST when clinical breakpoints are established, including dosing 271 
information, MIC distributions, ECOFFs, preclinical and clinical PK/PD, Monte Carlo simulations and PK/PD 272 
breakpoints and clinical data [32]. For ECOFF setting, at least five datasets, each consisting of at least 15 273 
MICs, in total comprising at least 100 MICs, and with the modal MIC within ± 1 two-fold dilution from the 274 
most common modal MIC. This amount of data is often not available and then breakpoints are set with the 275 
available data when deemed appropriate. An example is the breakpoints set for C. dubliniensis because the 276 
close resemblance to C. albicans with respect to phylogeny, clinical infections and MICs.  277 
For the species infrequently causing human infections sufficient data for breakpoint setting will not be 278 
available in the near future. For some of these species however, available MIC data allow setting tentative 279 
or final ECOFFs. ECOFFs are informative regarding the upper limit of the wildtype distribution, and when a 280 
microorganism has acquired resistance mechanisms, indicating that the clinical outcome may deviate from 281 
the general experience for that species. Moreover, ECOFFs allow a comparison with other species with 282 
respect to intrinsic susceptibility pattern. Therefore, an overview table of current EUCAST ECOFFs and 283 
breakpoints has been released this year and summarised as Tables 4 and 5. Until, species specific clinical 284 
breakpoints are established for the rarer species, a pragmatic approach is to prefer an antifungal agent for 285 
which the ECOFF does not exceed that for the most common species in that genus. The rationale behind 286 
this advice is that the most common species within a genus is in general the most virulent one and hence, 287 
what is appropriate to treat this organism is likely also appropriate for infections caused by other species 288 
with similar susceptibility patterns in vitro from that same genus. For C. lusitaniae for example the tentative 289 
amphotericin B ECOFF is equal to that for C. albicans whereas the fluconazole ECOFF is 32 times higher 290 
suggesting that amphotericin B should be preferred. EUCAST AFST is in the process of setting ECOFFs for a 291 
number of compounds and less common species. These ECOFFs will be released in due course. 292 
 293 
Conclusion 294 
The EUCAST AFST has reviewed all and revised many breakpoints for the antifungal agents to implement 295 
the revised EUCAST 2019 change in definitions of susceptibility categories S, I and R, especially relevant for 296 
the definition of “I” as “Susceptible, Increased exposure”. “I” has been retained for fluconazole and 297 
voriconazole against all Candida species with advice on a dose escalation. An ATU has been introduced for 298 
micafungin against C. albicans and for isavuconazole and posaconazole against some Aspergillus species 299 
with the advice to use a “marker compound” to determine if the MIC in the ATU should be reported as S or 300 
R. ATU has also been introduced for itraconazole and voriconazole against several Aspergillus species with 301 
the recommendation to report as R but with the comment that the compounds may be considered for less 302 
severe non-invasive infections provided good drug exposure is achieved and ensured. We hope these 303 
changes will reduce confusion on how to act on S, I and R categories. S is for Susceptible, and for Similar 304 
response as in other patients on Standard dose. I is for susceptible Increased exposure, and for Intelligence 305 
needed as Increased dosage is Important, and R is for Resistance, and for Risk because change of therapy is 306 
Required.  307 
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Table 1. EUCAST breakpoints for Candida species valid from 04-02-2020. New or revised breakpoints are underscored. ATU, Area of Technical 
Uncertainty, is a single MIC value, the interpretation of which can be performed via the regular breakpoints but which often needs further attention 
as explained in footnotes. 
Antifungal 
agent 
Candida 
albicans 
 Candida 
dubliniensis 
 Candida 
glabrata 
 Candida 
krusei 
 Candida 
parapsilosis 
 Candida 
tropicalis 
 Non-species related 
breakpoints
1
 
S ≤ R > ATU  S ≤ R >  S ≤ R >  S ≤ R >  S ≤ R >  S ≤ R >  S ≤ R > 
Amphotericin B
2 
1 1   1 1  1 1  1 1  1 1  1 1  IE IE 
Anidulafungin
2,3 
0.03 0.03      0.06 0.06  0.06 0.06  4 4  0.06 0.06  IE IE 
Fluconazole
4 
2 4   2 4  0.001
5
 16  - -  2 4  2 4  2 4 
Itraconazole
2 
0.06 0.06   0.06 0.06  IE
6
 IE
6
  IE
6
 IE
6
  0.125 0.125  0.125 0.125  IE IE 
Micafungin
2,3
  0.016 0.016 0.03
7 
    0.03 0.03  IE
8
 IE
8
  2 2  IE
8
 IE
5
  IE IE 
Posaconazole
2 
0.06 0.06   0.06 0.06  IE
6
 IE
6
  IE
6
 IE
6
  0.06 0.06  0.06 0.06  IE IE 
Voriconazole
9 
0.06
10
 0.25
10
   0.06
10
 0.25
10
  IE IE  IE IE  0.125
10
 0.25
10
  0.125
10
 0.25
10
  IE IE 
- No breakpoints. Susceptibility testing is not recommended. 
IE Insufficient evidence that the organism or group is a good target for therapy with the agent. 
1
 Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific 
Candida species. They are for use only for organisms that do not have specific breakpoints. 
2
 No data to support an I category for amphotericin B according to the new definition of I 
3 
Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints 
have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges 
for caspofungin. 
4
 High dose for fluconazole is required isolates in the I-category 
5
 The entire C. glabrata is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category 
(≤0.001 mg/L) is simply to avoid missclassification of "I" strains as "S" strains. 
6 
The ECOFFs for these species are in general higher than for C. albicans. 
7 
If S to anidulafungin, report as S and add the following comment: "Isolates susceptible to anidulafungin with micafungin MIC of 0.03 mg/L do not 
harbour an fks hot spot mutation conferring resistance to the echinocandins". 
If not S to anidulafungin, report as R and refer to reference laboratory for fks sequencing and confirmation of MICs. 
8
 Micafungin MICs for C. tropicalis are 1-2 two-fold dilution steps higher than for C. albicans and C. glabrata. In the clinical study successful outcome 
was numerically  slightly lower for C. tropicalis than for C. albicans at both dosages (100 and 150 mg daily). However, the difference was not 
significant and whether it  translates into a relevant clinical difference is unknown. MICs for C. krusei are approximately three two-fold dilution steps 
higher than those for C. albicans and, similarly, those for C. guilliermondii are approximately eight two-fold dilutions higher. In addition, there were 
only a small number of cases involved these species in the clinical trials. This means there is insufficient evidence (IE) to indicate whether the wild-
type population of these pathogens can be considered susceptible to micafungin. 
9
 For Candida the I category is introduced to acknowledge that the increased exposure obtained by iv dosing is sufficient (potentially confirmed by 
TDM). There is not enough information available for the response to voriconazole of infections caused by Candida isolates with higher MICs. 
10
 Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such 
isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for 
confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in 
infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of 
C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible. 
  
Table 2. EUCAST breakpoints for Aspergillus species valid from 04-02-2020. New or revised breakpoints are highlighted in underscored font. ATU, Area 
of Technical Uncertainty, is a single MIC value, the interpretation of which can be performed via the regular breakpoints but which often needs 
further attention as explained in footnotes.  
Antifungal agent A. flavus  A. fumigatus  A. nidulans  A. niger  A. terreus 
S ≤ R > ATU  S ≤ R > ATU  S ≤ R > ATU  S ≤ R >  S ≤ R > ATU 
Amphotericin B
1
 - -   1 1   - -   1 1  - -  
Isavuconazole
2,3 
1 2 2
4 
 1 2 2
4 
 0.25 0.25   IE
5
 IE
5
  1 1  
Itraconazole
1,3,6
 1 1 2
7 
 1 1 2
7 
 1 1 2
7 
 IE
5
 IE
5
  1 1 2
7 
Posaconazole
3,6,8
 IE
5
 IE
5
   0.125 0.25 0.25
9 
 IE
5
 IE
5
   IE
5
 IE
5
  0.125 0.25 0.25
9 
Voriconazole 
1,3,6
 IE
5
 IE
5
   1 1 2
10 
 1 1 2
10 
 IE
5
 IE
5
  IE
5
 IE
5
  
- No breakpoints. Susceptibility testing is not recommended. 
IE Insufficient evidence that the organism or group is a good target for therapy with the agent. 
1
 No data to support an "I" category according to the new definition of "I" 
2
 Isavuconazole MIC = 2 mg/L should not be interpreted as I but only as ATU 
3
 Itraconazole and posaconazole R isolates but S to voriconazole and isavuconazole are not uncommon in azole-treated patients. Refer the isolate to a 
reference laboratory for CYP51A sequencing and confirmation of MICs. 
4
 If voriconazole wild-type: (A. flavus: voriconazole MIC ≤2 mg/L;  A. fumigatus: voriconazole MIC ≤1 mg/L) report as isavuconazole S and add the 
following comment: The MIC of 2 mg/L is one dilution above the S breakpoint but within the wild-type isavuconazole MIC range due to a stringent 
breakpoint susceptibility breakpoint. See rationale documents for more information. 
If voriconazole non wild-type: report as isavuconazole R and refer to reference laboratory for CYP51A sequencing and confirmation of MICs." 
5
 The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus 
6
 Monitoring of azole trough concentrations in patients treated for fungal infection is recommended. 
7
 Report as R with the following comment: "In some clinical situations (non-invasive infections forms) itraconazole can be used provided sufficient 
exposure is ensured". 
8
 Normally, values between the S and R categories should be classified as “I”, but in the case of Posaconazole and A. fumigatus MIC = 0.25 mg/L 
should not be interpreted as I but only as ATU. How to act on this is described in footnote 
9
. 
9
 If S to itraconazole: report as S and add the following comment: "The MIC is 0.25 mg/L and thus one dilution above the S breakpoint due to 
overlapping wt and non-wt populations". 
If not S to itraconazole: report as R and refer to reference laboratory for CYP51A sequencing and confirmation of MICs. 
10
 Report as R with the following comment: "In some clinical situations (non-invasive infections forms) voriconazole can be used provided sufficient 
exposure is ensured". 
  
Table 3. "EUCAST breakpoints are based on the adult dosages indicated below. Alternative dosing regimens which result in equivalent exposure are 
acceptable. The table should not be considered an exhaustive guidance for dosing in clinical practice. The table neither replaces specific local, 
national, or regional dosing guidelines, nor does it replace manufacturer’s licensed dosage recommendations according to SPCs.   
    
Azoles Standard dose
1 
Increased 
Exposure Dose 
Special situations 
Fluconazole A single initial dose of 800 mg followed by 400 mg 
once daily (or 6 mg/kg) iv/oral 
800 mg (or 12 
mg/kg) once-
daily iv/oral 
Indicated doses are those appropriate for invasive 
candidiasis 
Mucosal infections (Mendling et al; Mycoses. 2012;55 
Suppl 3:1-13): Standard doses is 100-200 mg once daily 
and increased dose 800 mg once daily (for C. glabrata) 
Itraconazole 200 mg twice daily the first day followed by 100*-
400** mg daily iv/po 
Target trough level***: >0.5 mg/L for prophylaxis, >1 
mg/L for therapy 
 *Superficial infections only 
**Daily doses up to 200 mg twice daily may be given 
depending on the infection. Capsules have 30% lower 
bioavailability than the oral solution                                                    
***HPLC assay method and Parent compound only. 
Isavuconazole 200 mg three times daily for 2 days followed by 200 
mg once daily 
  
Posaconazole Tablets/iv: 300 mg twice daily the first day followed 
by 300 mg once daily 
Oral suspension: 200 mg four times daily or 400 mg 
twice daily 
Target trough level: >0.7 mg/L for prophylaxis / >1.25 
mg/L for therapy 
  
Voriconazole 6 mg/kg twice daily the first day followed 4 mg/kg 
twice daily iv  
400 mg twice daily followed by 200 mg twice daily po 
Target trough level: >0.5 for prophylaxis, 2-5.5 mg/L 
for therapy 
Candida: The I-
category only 
applies for the 
iv dosage (not 
the standard 
oral dose) 
Increased exposure can be achieved by elevated dosage 
(note non-linear kinetics in adults) or with a proton pump 
inhibitor, in patients with low blood levels. 
Amphotericin B 
formulations 
Standard dose Increased 
Exposure Dose 
Special situations 
Liposomal 
amphotericin B 
3 mg/kg once daily  Increased doses up to 7 mg/kg (or even 10 mg/kg e.g. 
Mucorales CNS infections) can be used in specific 
situations. 
Amphotericin B 
deoxycholate 
1 mg/kg once daily   
ABLC 5 mg/kg once daily   
Echinocandins Standard dose Increased 
Exposure Dose 
Special situations 
Anidulafungin A single initial dose of 200 mg followed by 100 mg 
once daily 
  
Caspofungin A single initial dose of 70 mg followed by 50* mg 
once daily (weight ≤ 80 kg) or  
70 mg once daily (weight > 80 kg) 
 *Continue with 70 mg once daily after loading dose if 
weight >80 kg 
Micafungin 100 mg once daily (weight >40 kg) 
2 mg/kg once daily in patients weighing <40 kg 
200 mg once 
daily (weight 
>40 kg) 
4 mg/kg once 
daily in 
patients 
weighing <40 
kg 
Increased dose indicated in patients not responding to 
standard dose 
Standard dose for chronic aspergillosis is Micafungin 150 
mg once daily (Chronic pulmonary aspergillosis: rationale 
and clinical guidelines for diagnosis and management.  
Eur Resp J 2016) 
 
1 
Duration of treatment only indicated for loading doses, because the total duration of therapy is not only dependent on the type and site of infection 
but also on the underlying disease of the patient. Please consult clinical management guidelines for recommendations on total duration." 
  
Table 4. Summary table of current EUCAST ECOFFs (WT ≤; mg/L, in blue) and susceptibility breakpoints (S ≤; mg/L, in black) for Candida species, 
Saccharomyces (S.) cerevisiae and Cryptococcus (C.) neoformans and Cryptococcus gattii. Tentative ECOFFs are indicated in brackets
a
. ND (not done). – 
(dash) EUCAST recommends not to test as the species is intrinsically resistant to the agent in question. 
Drug  
 
Species  
Candida Saccharomyces 
cerevisiae 
Cryptococcus 
albicans dubliniensis glabrata krusei parapsilosis tropicalis guilliermondii lusitaniae kefyr neoformans gattii 
Amphotericin B  
        
 
   
WT ≤ 1 0.25 1 1 1 1 [0.5] [0.5] [1] [0.5] [1] [0.5] 
S ≤  1 1 1 1 1 1 ND ND ND ND 1 ND 
Anidulafungin  
        
 
   
WT ≤ 0.03 
 
0.06 0.06 4 0.06 
  
 
   
S ≤  0.03 
 
0.06 0.06 4 0.06 
  
 
 
- - 
Fluconazole  
        
 
   
WT ≤ 0.5 [0.5] 16 128 2 1 [16] 
 
[1] 
   
S ≤  2 2 0.001 - 2 2 ND 
 
ND 
   
Itraconazole  
        
 
   
WT ≤ 0.06 0.06 2 1 0.125 0.125 2 0.125  
   
S ≤  0.06 0.06 ND ND 0.125 0.125 ND ND  
   
Micafungin 
        
 
   
WT ≤ 0.016 
 
0.03 0.25 2 0.06 
  
 
   
S ≤  0.016 
 
0.03 ND 2 ND 
  
 
 
- - 
Posaconazole  
        
 
   
WT ≤ 0.06 0.06 1 0.5 0.06 0.06 0.25 
 
 
 
0.5 1 
S ≤  0.06 0.06 ND ND 0.06 0.06 ND 
 
 
 
ND ND 
Voriconazole  
        
 
   
WT ≤ 0.03 0.03 1 1 0.06 0.125 
  
 
 
0.5 
 
S ≤  0.06 0.06 ND ND 0.125 0.125 
  
 
 
ND 
 
a
 Tentative ECOFFs are set on dataset that do not full fill the criteria described in EUCAST SOP 10.1 available at the www.eucast.org website (e.g. 
fewer than 5 distributions, fewer than 100 isolates per species etc.) Tentative ECOFFs therefore may change when more data emerge.   
Table 5. Summary table of current EUCAST ECOFFs (WT ≤; mg/L, in blue) and susceptibility breakpoints (S ≤; mg/L, in black) for Aspergillus species, and 
Fusarium species. Tentative ECOFFs are indicated in brackets. ND (not done). – (dash) EUCAST recommends not to test as the species is intrinsically 
resistant to the agent in question. 
Drug 
Species 
A. flavus A. fumigatus A. nidulans  A. niger A. terreus Fusarium (Gibberella) fujikuroi SC Fusarium solani SC 
Amphotericin B  
 WT ≤  4 1 [4] [0.5] 8 [8] [8] 
S ≤  - 1 - 1 - ND ND 
Isavuconazole 
 WT ≤  2 2 0.25 4 1 
 S ≤  1 1 0.25 ND 1 
 Itraconazole       
WT ≤  1 1 1 4 0.5 
 S ≤  1 1 1 ND 1 
 
Posaconazole  
     
WT ≤  0.5 0.25 0.5 0.5 0.25 
 S ≤  ND 0.125 ND ND 0.125 
 
Voriconazole  
 WT ≤  2 1 1 2 2 
 S ≤  ND 1 1 ND ND 
  
